Skip to main content
Journal cover image

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Publication ,  Journal Article
Ge, D; Fellay, J; Thompson, AJ; Simon, JS; Shianna, KV; Urban, TJ; Heinzen, EL; Qiu, P; Bertelsen, AH; Muir, AJ; Sulkowski, M; McHutchison, JG ...
Published in: Nature
September 17, 2009

Chronic infection with hepatitis C virus (HCV) affects 170 million people worldwide and is the leading cause of cirrhosis in North America. Although the recommended treatment for chronic infection involves a 48-week course of peginterferon-alpha-2b (PegIFN-alpha-2b) or -alpha-2a (PegIFN-alpha-2a) combined with ribavirin (RBV), it is well known that many patients will not be cured by treatment, and that patients of European ancestry have a significantly higher probability of being cured than patients of African ancestry. In addition to limited efficacy, treatment is often poorly tolerated because of side effects that prevent some patients from completing therapy. For these reasons, identification of the determinants of response to treatment is a high priority. Here we report that a genetic polymorphism near the IL28B gene, encoding interferon-lambda-3 (IFN-lambda-3), is associated with an approximately twofold change in response to treatment, both among patients of European ancestry (P = 1.06 x 10(-25)) and African-Americans (P = 2.06 x 10(-3)). Because the genotype leading to better response is in substantially greater frequency in European than African populations, this genetic polymorphism also explains approximately half of the difference in response rates between African-Americans and patients of European ancestry.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Nature

DOI

EISSN

1476-4687

Publication Date

September 17, 2009

Volume

461

Issue

7262

Start / End Page

399 / 401

Location

England

Related Subject Headings

  • Viral Load
  • Recombinant Proteins
  • Polymorphism, Single Nucleotide
  • Polyethylene Glycols
  • Pharmacogenetics
  • Interleukins
  • Interferons
  • Interferon-alpha
  • Interferon alpha-2
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ge, D., Fellay, J., Thompson, A. J., Simon, J. S., Shianna, K. V., Urban, T. J., … Goldstein, D. B. (2009). Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 461(7262), 399–401. https://doi.org/10.1038/nature08309
Ge, Dongliang, Jacques Fellay, Alexander J. Thompson, Jason S. Simon, Kevin V. Shianna, Thomas J. Urban, Erin L. Heinzen, et al. “Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.Nature 461, no. 7262 (September 17, 2009): 399–401. https://doi.org/10.1038/nature08309.
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009 Sep 17;461(7262):399–401.
Ge, Dongliang, et al. “Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.Nature, vol. 461, no. 7262, Sept. 2009, pp. 399–401. Pubmed, doi:10.1038/nature08309.
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009 Sep 17;461(7262):399–401.
Journal cover image

Published In

Nature

DOI

EISSN

1476-4687

Publication Date

September 17, 2009

Volume

461

Issue

7262

Start / End Page

399 / 401

Location

England

Related Subject Headings

  • Viral Load
  • Recombinant Proteins
  • Polymorphism, Single Nucleotide
  • Polyethylene Glycols
  • Pharmacogenetics
  • Interleukins
  • Interferons
  • Interferon-alpha
  • Interferon alpha-2
  • Humans